ArticleWorld journal of surgical oncology2026
Clinical characteristics and prognosis of familial non-medullary thyroid carcinoma: a retrospective study of 98 families.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe differences in clinicopathological features and prognosis between familial non-medullary thyroid carcinoma (FNMTC) and sporadic non-medullary thyroid carcinoma (SNMTC) remain a subject of debate. This study aims to compare the clinicopathological features and recurrence-free survival (RFS) between FNMTC and SNMTC, with a particular focus on the subgroup differences based on the number of affected relatives.
methodsA retrospective analysis was conducted on 672 NMTC patients who underwent thyroidectomy at West China Hospital between 2015 and 2024. The cohort included 224 FNMTC patients (from 98 families) and 448 SNMTC patients. FNMTC patients were further stratified into families with two affected members (FNMTC-2, n = 160) and families with ≥ three affected members (FNMTC-3, n = 64) subgroups. Clinicopathological characteristics and RFS were compared among the groups.
resultsCompared to the SNMTC group, the FNMTC group demonstrated a smaller tumor diameter (1.03 ± 0.60 cm vs. 1.15 ± 0.96 cm, p = 0.0255) but higher rates of multifocality (43.75% vs. 34.82%, p = 0.024), bilaterality (32.59% vs. 23.88%, p = 0.0163), and lymph node metastasis (52.68% vs. 44.42%, p = 0.0432). Subgroup analysis revealed that the FNMTC-3 group, compared to SNMTC, was associated with a younger age at diagnosis (43.76 ± 14.53 vs. 47.01 ± 11.28 years, p = 0.039), a smaller tumor diameter (0.89 ± 0.46 cm vs. 1.15 ± 0.96 cm, p = 0.0343), and increased rates of multifocality (50.00% vs. 34.82%, p = 0.0185), bilaterality (37.50% vs. 23.88%, p = 0.0195), lymph node metastasis (57.81% vs. 44.42%, p = 0.0444), and thyroid follicular nodular disease (57.81% vs. 44.20%, p = 0.0409). Furthermore, the FNMTC-3 group had a significantly smaller tumor diameter than the FNMTC-2 group (0.89 ± 0.46 cm vs. 1.08 ± 0.64 cm, p = 0.0343). However, no statistically significant differences in RFS were observed among the SNMTC and FNMTC groups during follow-up.
conclusionFNMTC-3 exhibits more aggressive clinicopathological features than SNMTC, including earlier onset, higher multifocality, bilaterality, and metastatic potential. These findings support that the number of affected family members is a significant indicator of tumor aggressiveness in FNMTC. Although no difference in RFS was observed, the distinct pathological profile of FNMTC-3 warrants more vigilant surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.